A two part, Phase I open label dose escalation and expansion study to assess the safety, pharmacokinetics and clinical activity of NUC-7738, a nucleotide analogue, in patients with advanced solid tumours

Research summary

This is a research study to test a new investigational drug called NUC-7738. NUC-7738 belongs to a new class of anti-cancer agents called ProTides that are specifically designed to transform some of the most widely prescribed chemotherapy agents, nucleoside analogues, into more effective and safer medicines. The primary objective of this study is to investigate the safety and tolerability of NUC-7738 in subjects with solid tumours or lymphomas. This is a first-in-man study. The study is funded by NuCANA plc, an Edinburgh based company. Subjects who have solid tumours or lymphomas will be recruited from 3 hospitals in the UK. These subjects will receive the investigational drug in small groups at escalating doses in order to find the safest dose tolerated. The study will last for around 2 years and subjects will be in the study for approx. 7 months.

Principal Investigator

Dr Miranda Payne

Contact us

Email: orh-tr.earlyphasenurses@nhs.net

IRAS number

253656